Ovarian cancer (OC) is the eighth leading cause of cancer-related deaths among women. This study aimed to evaluate multiple functional genes involved in OC pathogenesis and diagnosis. The expression profiling of Fos Proto-Oncogene, Activator Protein-1 Transcription Factor Subunit (FOS), FOS Like 2, Activator Protein-1 Transcription Factor Subunit (FOSL2), Activator Protein-1 Transcription Factor Subunit Jun Proto-Oncogene (JUN), Matrix Metalloproteinases 2 (MMP-2), Matrix Metalloproteinases 9 (MMP-9) and Tissue Inhibitor of Metalloproteinase 2 (TIMP-2) and Vascular Endothelial Growth Factor (VEGFA) was performed using quantitative real-time PCR (qRT-PCR) in healthy ovary tissues (n=10) and high-grade serous OC tissues (n=10). Functional gene set and pathway analysis were conducted by the g: profiler web server. Gene Expression Profiling Interactive Analysis (GEPIA) was used for pathological stage and overall survival analysis in the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) datasets.qRT-PCR results revealed that FOS (P-value = 0.0089), MMP-9 (P-value = 0.0029), and VEGFA (P-value = 0.0434) were upregulated. FOSL2 (P-value = 0.0271), JUN (P-value = 0.0041), and TIMP-2 (P-value = 0.0062) were downregulated. Pathway enrichment analysis showed that the relaxin signaling pathway was the most significant (FDR=9.38e-08) biological pathway. The FOSL2 and TIMP-2 are significant in overall survival and pathological stage analysis, respectively. The analyzed genes may have the potential for personalized diagnosis and treatment.
Aim: Ovarian cancer (OC) is the most lethal gynecologic malignancy and frequently diagnosed at an advanced stage because of the inadequate number of biomarkers. Therefore, identification of OC specific biological markers is a vital step for diagnosis and treatment response. Our goal is to examine functional gene sets which are possibly markers for ovarian cancer and their expression profiles in OC patients. We also aim to determine the potential genes for therapeutic targets for OC patients. Method: The expression levels of seven genes (FOS, FOSL2, JUN, MMP-2, MMP-9, TIMP-2, and VEGFA) were identified by qRT-PCR. The tumor-free control group consisted of total abdominal hysterectomy (n=1) and bilateral salpingo-oophorectomy (n=9) patients who underwent gynecologic procedures. High-grade serous OC epithelial samples (n=10) were used for the experiment group. Results and Conclusions: According to the qRT-PCR data, there is an increased expression of FOS (p=0.0089), MMP-9 (p=0.0029), VEGFA (p=0.0434) and decreased expression of FOSL2 (p=0.0271), JUN (p=0.0041), TIMP-2 (p=0.0062). In conclusion, the results can indicate the new perspective for OC pathogenesis and treatment. For future studies, these genes can be used in personalized diagnosis and therapy of OC.